Global Elderly Demand And Biosimilars Will Transform Healthcare

AN
AnalystConsensusTarget
Consensus Narrative from 14 Analysts
Published
07 Nov 24
Updated
07 Aug 25
AnalystConsensusTarget's Fair Value
€48.83
10.4% undervalued intrinsic discount
07 Aug
€43.74
Loading
1Y
41.6%
7D
6.4%

Author's Valuation

€48.8

10.4% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on01 May 25
Fair value Increased 3.65%

Shared on23 Apr 25
Fair value Decreased 0.085%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on17 Apr 25
Fair value Decreased 3.34%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25
Fair value Increased 3.45%

Shared on02 Apr 25
Fair value Decreased 17%

AnalystConsensusTarget has decreased future PE multiple from 17.7x to 14.6x.

Shared on26 Mar 25
Fair value Increased 27%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on19 Mar 25
Fair value Decreased 7.97%

AnalystConsensusTarget has increased future PE multiple from 14.9x to 17.2x.

Shared on12 Mar 25
Fair value Increased 85%

AnalystConsensusTarget has increased revenue growth from 2.6% to 4.5%, increased future PE multiple from 12.5x to 14.9x and decreased shares outstanding growth rate from 0.1% to 0.0%.